



TO THE **HEART** OF THE DATA | TREATMENT AND PREVENTION OF COMPLICATIONS FOR PEOPLE WITH **T2D**



Meeting moderator:
Professor Michael d’Emden

Professor Michael d’Emden graduated from University of Tasmania in 1978. He was a resident and registrar at the Princess Alexandra Hospital in Brisbane before moving to Royal Melbourne Hospital in 1983. He obtained his fellowship in 1985, completed a PhD at University of Melbourne in 1988 before doing further studies at the University of Iowa.

He is now the Director of the Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital (RBWH), a Clinical Associate Professor of the University of Queensland and was the vice president of the Australian Diabetes Society 2012-2014. His major clinical interests are the association of diabetes with cardiovascular disease, and lipid metabolism. He serves on many national advisory boards as well as having been a member of the International Management committees of the FIELD, ASPEN and TNT studies. He heads an active clinical research unit at the RBWH and was the principle Australian investigator of the EMPA-REG and DECLARE studies and several other SGLT2i studies.



Speaker:
Professor Subodh Verma

Dr Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the Canada Research Chair in Cardiovascular Surgery and a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He served as Canada Research Chair in Atherosclerosis for 10 years from 2007-2017. He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar, Dr Verma’s work has been cited over 33,000 times resulting in an h-index of 87.

Dr Verma has published numerous times in prestigious journals like the NEJM, Lancet, Circulation, JBC, JACC, Nature, and JCI. He continues to be an active contributor to several CCS guidelines; he co-authored the 2018 Diabetes Canada guidelines as well as the 2018 AATS consensus guidelines on bicuspid aortic valve-related aortopathy. Dr Verma has served on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr Verma has leadership roles on 7 ongoing global heart failure trials in diabetes – DAPA-HF, DELIVER, DETERMINE-A, DETERMINE-B, EMPEROR-Preserved, EMPEROR-Reduced and SOLOIST-WHF – as well as the SELECT (semaglutide) and CLEAR SYNERGY (OASIS 9) trials. He oversees the CardioLink platform that is conducting surgically oriented RCTs and translational studies.

Dr Verma oversees a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. This research has yielded 2 United States patents and is currently supported by the Canadian Institutes of Health Research (CIHR) and HSF.

Agenda

7.30 pm	Welcome & Introduction	Professor Michael d’Emden
7.35 pm	Cardiovascular Outcomes DECLARE-TIMI 58	Professor Subodh Verma
8.05 pm	Renal Outcomes DECLARE-TIMI 58	Professor Subodh Verma
8.20 pm	Q & A	Professor Subodh Verma Professor Michael d’Emden
8.30 pm	Close	Professor Michael d’Emden